Navigating the complexities of patenting AI inventions

AI innovation is moving fast—but can the patent system keep up? Drafting patents for AI systems isn’t just about protecting technology; it’s about bridging the gap between coders, technical experts, and legal frameworks.

 

With evolving regulations and the challenge of defining inventorship, securing strong IP protection requires careful strategy. Two IP patent attorney and AI expert Dr Coreena Brinck shares what you need to know.

Drafting patents for AI systems presents a complex array of challenges, particularly when it comes to inventions involving inventor teams who may be experts in different disciplines.

AI inventions can often be a result of collaborative efforts between coders, technical specialists in various areas, for example, medicine, and commercial managers, each with their own understanding of what the invention is, and possibly each having their own technical language to describe what may be the same thing in practice. 

On top of this, are the various ways that code can be generated for any computer-implemented invention these days. For example, many coders and programmers rely on libraries of code snippets or pre-existing code modules and computer models to build their own platforms and systems and some also use generative AI applications to automatically generate source and/or executable programs using prompts (an example here being Claude, also available as a mobile phone app). This can lead to a lack of awareness over implementation and may bring additional challenges and complexity not just from describing how to implement an invention but also when it comes to identifying who exactly made various inventive contributions.  The later is essential not just as the fundamental right to a granted patent rests with the inventor(s) unless assigned away, for example, to their employer, but also as only humans can currently have such ownership rights and this means non-human inventors are not allowed by patent offices.

Patenting complex technology accordingly means professional help may be crucial for success.  Not only can a patent attorney help assess whether an invention is eligible for patent protection, but they can also determine who should be named as an inventor in view of their contribution to the invention.    A patent attorney can also keep track of your patent application as it progresses which may include revisiting the question of inventorship as the inventors listed in the initial patent claims may differ from those who are ultimately listed in the granted claims, making the process even more fluid and challenging.

The issue of AI-assisted inventorship is further complicated as different patent offices have different guidelines and regulations.  As of February 2025, the European Patent Office (EPO) does not allow non-human inventors to be named on patent applications. This rule means that AI systems, while they may play a significant role in the invention, cannot be listed as inventors, even though they may arguably have contributed to generating part or all of the inventive idea.

In patent drafting, a key challenge for protecting inventions involving applied AI, where a known AI model is used in a new way for a particular application, may be simply identifying what AI model(s) can be used in the invention and how their features and characteristics, including how the AI system is trained and functions operationally, contributes to a technical effect.  The inventors may not have thought of their invention in this manner and it can be perplexing for them to understand what information they may need to share with their patent attorney so that the patent specification includes sufficient information to “teach” how their invention can be implemented by others skilled in that technical field.

Assessing what is sufficient information is not straight forward and can be particularly challenging for core-AI inventions.  In some situations, during the training stage, details such as the volume, source, and cleaning/pre-processing of training data may need to be provided. What counts as “trained” and when the training process should stop may be other important factors to describe for some models.  The weight learning algorithm of the ANN and initialization methods may need to be explained for some core models and it may be that a training method contributes to a different technical effect from that provided by the trained ANN model. The various possible training methods may also need to be described, and whether one or more different types of training are possible.  For example, training may be supervised, unsupervised, on-going or continuous, in some situations.

If the training is on-going, it is crucial to describe what this means, as well as how errors are measured ongoingly and how this can impacts the performance of the model.

The operational stage of the AI system may be the core commercial proposition that the applicant wants to protect from its competitors.  In this case, how the trained AI system is being used should be explained, and a causal link provided including any post-processing of its output so that the AI system as claimed provides a patentable technical effect.

Finally, given the ongoing evolution of AI technology and regulatory frameworks, considerations like the EU AI Act are become increasingly important. Inventors and patent professionals must navigate the fine line between patenting the AI system, protecting trade secrets, and utilizing open-source and defensive publications to safeguard innovations without over-disclosing sensitive details.

Ultimately, patent drafting in the AI space requires clear communication among diverse stakeholders with varying levels of expertise, clear and consistent language to be used in documentation of both the technical and operational stages, and some understanding of the AI regulatory landscape is also helpful. Successfully balancing technical disclosure, confidentiality, and patentability is what makes AI patent drafting a particularly complex and evolving field – as well as why I so enjoy working in this area.

If you are seeking guidance on protecting your AI inventions, you can contact Coreena via our website here or email us at hello@two-ip.com

Innovation saves lives – but only if we protect it

During the COVID-19 crisis, we saw a spike in vaccine patent applications – but why does that matter? Because intellectual property rights (IPR) aren’t just legal protections; they’re the foundation of life-saving innovation. Without them, groundbreaking research wouldn’t have scaled into global solutions.

Curious about why IPRs matter to biotech and life sciences innovators, and how their use played out in the COVID-19 pandemic and beyond? Two IP patent attorney Sheena Linehan explains more. 

In the realm of biotech and life sciences, the ‘Why’ of protecting intellectual property (IP) is deeply connected to the mission to advance human health. Safeguarding IP is essential for fostering innovation, allowing groundbreaking medical discoveries to be developed and scaled to address pressing health challenges.

Why protecting Intellectual Property matters

The primary purpose of intellectual property rights (IPR) in this sector is to incentivise the development of new medical solutions. The process of creating vaccines, therapies, and medical technologies demands significant investment in research and development. By securing IP, organisations can protect their innovations from unauthorised use, allowing them to recoup investments and fund further research. This protection is crucial for translating scientific discoveries into accessible health solutions that benefit society at large.

Securing patents and other IP rights allows organizations to:

Secure investment for R&D and clinical trials

Form strategic partnerships for clinical development and large-scale manufacturing

Enter new markets and foster global accessibility through licensing and collaborations

The COVID-19 pandemic highlighted a critical role for IP in public health. The University of Oxford developed a candidate COVID-19 vaccine ChAdOx1 and secured its IP. To ensure widespread access, they licensed this IP to AstraZeneca, which carried out clinical trials and franchised production to global partners, facilitating mass production and distribution. AstraZeneca notably partnered with the Serum Institute of India (SII), which alone manufactured over a billion doses. This collaboration was pivotal in delivering vaccines to low- and middle-income countries, demonstrating how strategic IP management can serve the public interest.

How IPR fuels ongoing innovation

The benefits of IP protection don’t end with one breakthrough. Following the success of the COVID-19 vaccine partnership, SII has pledged £50 million for a vaccines research facility at Oxford University, and has partnered with the University in development of the R21/Matrix-M malaria vaccine, which it will manufacture on a large scale.

Companies like Moderna and BioNTech, pioneers of mRNA vaccine technology, utilised their IP to rapidly develop COVID-19 vaccines, primarily for high-income countries. Post-pandemic, they are exploring the application of mRNA technology to cancer vaccines, showcasing how robust IP portfolios can drive ongoing innovation to address various health issues.

What are Intellectual Property Rights?

Intellectual Property Rights are legal protections granted to creators and innovators. In the biotech and life sciences sectors, these typically include:

  • Patents: Protect new inventions, such as novel biologics and their medical uses, and medical devices, for a limited period of up to 20 years.
  • Trade Secrets & Confidential Information: Protect proprietary formulae, research data, and manufacturing processes etc.
  • Trademarks: Safeguard brand names and logos, ensuring market identity.
  • Designs: Protect the unique appearance or design of a product, such as a medical device, for a limited period of up to 25 years.

These rights ensure that innovators can control the use of their creations, providing a framework to monetise their inventions and fund further research.

Impact of IPR on health

Owning IPRs significantly influences the ability of biotech and life sciences companies to address health challenges. The COVID-19 pandemic led to a substantial increase in vaccine patent applications, reflecting a surge in innovation aimed at combating the virus. This surge was driven by the need to develop effective vaccines rapidly, highlighting how IP protection can stimulate the creation of solutions to global health crises.

Moreover, strategic IP management facilitated collaborations that were essential for large-scale vaccine production and distribution. The partnership between AstraZeneca and SII, underpinned by IP licensing agreements, enabled the delivery of vaccines to numerous countries, exemplifying how IP can be leveraged to enhance global health outcomes.

In essence, for biotech and life sciences companies, the belief encapsulated in obtaining IPR is that innovation is a catalyst for improving health. Protecting IP not only rewards innovators but also ensures that their innovations can be developed, scaled, and distributed to address critical health challenges, ultimately serving the greater good.

Biotech Leaders – Protect your innovations

Biotech and life sciences companies must take action to protect their IP. Without it, groundbreaking research can be copied, funding becomes harder to secure, and the path to global impact becomes uncertain.

Our patent and trade mark attorneys can help you work out what you should be doing and then help you do it. To get in touch, click here or email us at hello@two-ip.com.

💡Found this information useful? Click here to sign up for our monthly Two Insights newsletter.

Sources:

astrazeneca.com

£50m funding for Poonawalla Vaccines Research Building at Oxford University | University of Oxford

Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out | University of Oxford

Merck and Moderna’s mRNA cancer vaccine aces its first efficacy trial | pharmaphorum

Promising lung cancer vaccine trial starts in UK – BBC News